The upcoming Triple-/MBC Trial (MSKCC/Collab.) @ProvidenceCC = SUNRISE/Ph.3 Site too...
1-11-16 PR, “Peregrine Provides Update on Planned Expansion of Bavi Clinical Pgm in Lung, Breast and Other Cancers”… http://tinyurl.com/zhdy37a PLANNED TRIALS... #4. Phase II Trial in Early Stage TNBC in Combination with Chemotherapy Peregrine is planning to initiate a Phase II trial of bavituximab in combination with neoadjuvant chemotherapy in early stage TNBC. The primary endpoint of this study is to determine the pathologic complete response rate (pCR), an accepted surrogate endpoint in early stage TNBC. The concept for this neoadjuvant setting trial, which will be conducted at a few select U.S. sites, originated from Peregrine's ongoing collaboration with Memorial Sloan Kettering Cancer Center (MSKCC). The company has filed a study protocol to its existing bavituximab IND application in the U.S. and is currently working to open clinical trial sites, including one that will be led by David B. Page, MD, at the Providence Cancer Center in Oregon [ http://oregon.providence.org/our-services/p/providence-cancer-center => http://oregon.providence.org/clinical-trials ]. ...Note: ProvidenceCC is a Ph.3 SUNRISE site, PI=Rachel Sanborn MD, Dir./ThoracicONCO http://cancergrace.org/faculty/rachel-sanborn-md Dr. Sanborn's Conflicts of interest: DNA, AZN - - - - - - - - Note DR. DAVID PAGE's prior work with Dr. Jedd Wolchok, chief of Mem.Sloan's Melanoma & Immunotherapeutics Service who “investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions”… http://www.bcrfcure.org/researchers/david-page
5-29-15/PR re: MSKCC/Peregrine Collab… http://tinyurl.com/zkvebh6 "The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Jedd Wolchok.
The studies at MSK will be performed under the direction of Taha Merghoub, PhD, [ http://www.mskcc.org/research-areas/labs/members/taha-merghoub-01 ] Associate Attending Biologist, Melanoma and Immunotherapeutics Service, Ludwig Collaborative and the Swim Across America Laboratory, a part of the laboratory of Jedd D. Wolchok, MD, PhD [ http://www.mskcc.org/research-areas/labs/jedd-wolchok ], a leader in the field of cancer immunotherapy. Dr. Wolchok serves as the Chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation as well as an Associate Director of the Ludwig Center for Cancer Immunotherapy at MSK.
"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Jedd Wolchok.
"A key focus of the WOLCHOK LAB's research is studying novel immunotherapy combinations that work together to enable the immune system to recognize and destroy cancer. This collaboration will allow us to focus on the role and contribution of PS blockade therapy in determining which combination of the current and next generation of immune modulators is likely to increase the extent and amplitude of anti-tumor response. This important pre-clinical and translational work will potentially guide the design of the next generation of clinical studies with bavituximab," said Dr. Merghoub.
= = = = = = = = = = = = = = = = = = = = = = = = = = = = 1-16-16: Summary of Peregrine's New Collab's: Mem.Sloan-Kettering, AstraZeneca, NCCN http://tinyurl.com/zkvebh6 I. Memorial Sloan Kettering (MSKCC) – 5-2015/Investigate Novel PS-Targeting Immunotherapy Combos II. AstraZeneca (Bavi+Durvalumab) - 8-2015/multiple solid tumors, 10-2015/expanded to NSCLC III. Natl-Comprehensive-Cancer-Network (NCCN) – 1-2016/$2mm grant to NCCN's Oncology Res. Pgm (ORP), “26 of the world's leading cancer centers”
Market Data 
Markets 
AI
